TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Online Intervention for Families Following Adolescent TBI - Teen Online Problem Solving (TOPS)
Brief Summary: The purpose of this study is to learn if using the World Wide Web to train teens and their families in problem-solving, communication skills, and stress management strategies can help them to cope better following traumatic brain injury (TBI). To answer this question, we will look at changes from before the intervention to after the intervention on questionnaire measures of problem-solving skills, communication, social competence, adjustment, and family stress and burden. We hypothesize that families receiving the TOPS intervention will have better parent-child communication and problem-solving skills at follow-up than those receiving the IRC intervention. Additionally, families receiving the TOPS intervention will have lower levels of parental distress, fewer child behavior problems and better child functioning than those receiving the IRC intervention. Lastly, treatment effects will be moderated by SES and life stresses, such that families with greater social disadvantage will benefit more from the TOPS intervention.


Options:
A: Intervention Type: BEHAVIORAL; Name: Problem-Solving Skills Training; Assigned to Arm(s): N/A
B: Arm Label: CALMA; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CALMA plus, Behavioral: CALMA | Arm Label: Calma plus; Type: EXPERIMENTAL; Interventions: Behavioral: CALMA plus | Intervention Type: BEHAVIORAL; Name: CALMA plus; Assigned to Arm(s): CALMA, Calma plus | Intervention Type: BEHAVIORAL; Name: CALMA; Assigned to Arm(s): CALMA
C: Arm Label: Multisystemic Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Multisystemic Therapy | Arm Label: Standard Medical Care (TAU); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Multisystemic Therapy; Assigned to Arm(s): Multisystemic Therapy
D: Arm Label: Teen Online Problem Solving; Type: EXPERIMENTAL; Interventions: Behavioral: Teen Online Problem Solving | Arm Label: Internet Resources Comparison; Type: EXPERIMENTAL; Interventions: Behavioral: Teen Online Problem Solving | Intervention Type: BEHAVIORAL; Name: Teen Online Problem Solving; Assigned to Arm(s): Internet Resources Comparison, Teen Online Problem Solving

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Online Intervention for Families Following Adolescent TBI - Teen Online Problem Solving (TOPS)
Brief Summary: The purpose of this study is to learn if using the World Wide Web to train teens and their families in problem-solving, communication skills, and stress management strategies can help them to cope better following traumatic brain injury (TBI). To answer this question, we will look at changes from before the intervention to after the intervention on questionnaire measures of problem-solving skills, communication, social competence, adjustment, and family stress and burden. We hypothesize that families receiving the TOPS intervention will have better parent-child communication and problem-solving skills at follow-up than those receiving the IRC intervention. Additionally, families receiving the TOPS intervention will have lower levels of parental distress, fewer child behavior problems and better child functioning than those receiving the IRC intervention. Lastly, treatment effects will be moderated by SES and life stresses, such that families with greater social disadvantage will benefit more from the TOPS intervention.


Options:
A: Arm Label: Teen Online Problem Solving; Type: EXPERIMENTAL; Interventions: Behavioral: Teen Online Problem Solving | Arm Label: Internet Resources Comparison; Type: EXPERIMENTAL; Interventions: Behavioral: Teen Online Problem Solving | Intervention Type: BEHAVIORAL; Name: Teen Online Problem Solving; Assigned to Arm(s): Internet Resources Comparison, Teen Online Problem Solving
B: Arm Label: Social learning and cognitive behavioral therapy (SLCBT); Type: EXPERIMENTAL; Interventions: Behavioral: Social Learning and Cognitive Behavioral Therapy (SLCBT) | Arm Label: Education Support (ES); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Education Support (ES) | Intervention Type: BEHAVIORAL; Name: Social Learning and Cognitive Behavioral Therapy (SLCBT); Assigned to Arm(s): Social learning and cognitive behavioral therapy (SLCBT) | Intervention Type: BEHAVIORAL; Name: Education Support (ES); Assigned to Arm(s): Education Support (ES)
C: Intervention Type: BEHAVIORAL; Name: Problem-Solving Skills Training; Assigned to Arm(s): N/A
D: Arm Label: Coaching group for lifestyle changes; Type: EXPERIMENTAL; Interventions: Behavioral: Coaching | Arm Label: Routine pediatric care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Coaching; Assigned to Arm(s): Coaching group for lifestyle changes

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety and Efficacy of Orally Administered Fx-1006A in Patients With Familial Amyloid Polyneuropathy (FAP): A Randomized, Double-blind, Placebo-controlled Study
Brief Summary: This study will examine whether Fx-1006A is effective in halting the progression of Familial Amyloid Polyneuropathy (FAP).

Deposition of TTR amyloid is associated with a variety of human diseases. Deposition of amyloid fibrils of variant TTR (primarily V30M) in peripheral nerve tissue produces the condition called FAP.

The prevention of the formation of amyloid by stabilization of the TTR native state should constitute an effective therapy for amyloid diseases. Therapeutic intervention with a TTR stabilizer drug, such as Fx-1006A, is hypothesized to stop progression of the disease in FAP patients. FAP is a uniformly fatal disease and Fx-1006A is intended to halt the relentless neurological deterioration FAP patients experience.

This Phase 2/3 study will enroll early to mid-stage FAP patients in order to interrupt and stabilize the disease at a point in time where progression of motor and autonomic dysfunction can be maximally effected. Male and female patients with FAP with documented V30M TTR mutation will receive Fx-1006A or placebo once daily for a period of eighteen (18) months.


Options:
A: Arm Label: 1.; Type: EXPERIMENTAL; Interventions: Drug: Fx-1006A | Arm Label: 2.; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fx-1006A; Assigned to Arm(s): 1. | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2.
B: Arm Label: Patisiran (ALN-TTR02); Type: EXPERIMENTAL; Interventions: Drug: Patisiran | Intervention Type: DRUG; Name: Patisiran; Assigned to Arm(s): Patisiran (ALN-TTR02)
C: Arm Label: patisiran (ALN-TTR02); Type: ACTIVE_COMPARATOR; Interventions: Drug: patisiran (ALN-TTR02) | Arm Label: Sterile Normal Saline (0.9% NaCl); Type: PLACEBO_COMPARATOR; Interventions: Drug: Sterile Normal Saline (0.9% NaCl) | Intervention Type: DRUG; Name: patisiran (ALN-TTR02); Assigned to Arm(s): patisiran (ALN-TTR02) | Intervention Type: DRUG; Name: Sterile Normal Saline (0.9% NaCl); Assigned to Arm(s): Sterile Normal Saline (0.9% NaCl)
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Fx-1006A | Intervention Type: DRUG; Name: Fx-1006A; Assigned to Arm(s): 1

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Brief Summary: The purpose of this study is to determine whether the cancer vaccine tecemotide (L-BLP25) in addition to best supportive care is effective in prolonging the lives of subjects with unresectable stage III non-small cell lung cancer, compared to best supportive care alone.

A local ancillary (sub) study in European centers will evaluate the immune response in peripheral blood after tecemotide (L-BLP25) or placebo vaccination.


Options:
A: Arm Label: Tecemotide (L-BLP25); Type: EXPERIMENTAL; Interventions: Biological: Tecemotide (L-BLP25), Drug: Single low dose cyclophosphamide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: Tecemotide (L-BLP25); Assigned to Arm(s): Tecemotide (L-BLP25) | Intervention Type: DRUG; Name: Single low dose cyclophosphamide; Assigned to Arm(s): Tecemotide (L-BLP25) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Investigational Arm; Type: EXPERIMENTAL; Interventions: Biological: Tecemotide, Drug: Single low dose cyclophosphamide, Other: Best Supportive Care (BSC) | Arm Label: Control Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Other: Saline, Other: Best Supportive Care (BSC) | Intervention Type: BIOLOGICAL; Name: Tecemotide; Assigned to Arm(s): Investigational Arm | Intervention Type: DRUG; Name: Single low dose cyclophosphamide; Assigned to Arm(s): Investigational Arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Control Arm | Intervention Type: OTHER; Name: Saline; Assigned to Arm(s): Control Arm | Intervention Type: OTHER; Name: Best Supportive Care (BSC); Assigned to Arm(s): Control Arm, Investigational Arm
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Biological: autologous dendritic cell adenovirus CCL21 vaccine | Intervention Type: BIOLOGICAL; Name: autologous dendritic cell adenovirus CCL21 vaccine; Assigned to Arm(s): Arm 1
D: Arm Label: GSK 249553 Group; Type: EXPERIMENTAL; Interventions: Biological: GSK 249553 vaccine | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: GSK 249553 vaccine; Assigned to Arm(s): GSK 249553 Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of a Comprehensive Weight Management Program on Obese Adolescents and Children
Brief Summary: To compare anthropometric and metabolic effects of a comprehensive weight management program on obese adolescents and children in comparison to regular clinical weight management visits.


Options:
A: Arm Label: Next.Step; Type: EXPERIMENTAL; Interventions: Other: Next.Step - e-therapeutic intervention program | Arm Label: Standard protocol; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard treatment protocol | Intervention Type: OTHER; Name: Next.Step - e-therapeutic intervention program; Assigned to Arm(s): Next.Step | Intervention Type: OTHER; Name: Standard treatment protocol; Assigned to Arm(s): Standard protocol
B: Intervention Type: BEHAVIORAL; Name: weight management program; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Reduction of sugar-sweetened beverage consumption | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Reduction of sugar-sweetened beverage consumption; Assigned to Arm(s): 1
D: Arm Label: CBT for depression and healthy lifestyle plus exercise; Type: EXPERIMENTAL; Interventions: Behavioral: CBT for depression and healthy lifestyle plus exercise | Arm Label: CBT for depression; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CBT for depression | Intervention Type: BEHAVIORAL; Name: CBT for depression and healthy lifestyle plus exercise; Assigned to Arm(s): CBT for depression and healthy lifestyle plus exercise | Intervention Type: BEHAVIORAL; Name: CBT for depression; Assigned to Arm(s): CBT for depression

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of a Comprehensive Weight Management Program on Obese Adolescents and Children
Brief Summary: To compare anthropometric and metabolic effects of a comprehensive weight management program on obese adolescents and children in comparison to regular clinical weight management visits.


Options:
A: Arm Label: Lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Structured Education | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Written Information | Intervention Type: BEHAVIORAL; Name: Structured Education; Assigned to Arm(s): Lifestyle counseling | Intervention Type: BEHAVIORAL; Name: Written Information; Assigned to Arm(s): Control
B: Intervention Type: BEHAVIORAL; Name: weight management program; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: PREPARE with pedometer | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: PREPARE | Intervention Type: BEHAVIORAL; Name: PREPARE with pedometer; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: PREPARE; Assigned to Arm(s): 2
D: Arm Label: Usual Care Only; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care Only | Arm Label: Vida Sana; Type: EXPERIMENTAL; Interventions: Behavioral: Vida Sana | Intervention Type: BEHAVIORAL; Name: Vida Sana; Assigned to Arm(s): Vida Sana | Intervention Type: OTHER; Name: Usual Care Only; Assigned to Arm(s): Usual Care Only

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Mental Health Outcomes of Child Brain Injury
Brief Summary: This study will evaluate the effectiveness of an Internet-based psychosocial treatment in improving problem-solving, communication skills, stress management strategies, and coping among children who have had a traumatic brain injury and their families.


Options:
A: Arm Label: family diabetes management intervention; Type: EXPERIMENTAL; Interventions: Behavioral: family diabetes management intervention | Intervention Type: BEHAVIORAL; Name: family diabetes management intervention; Assigned to Arm(s): family diabetes management intervention
B: Arm Label: CAPS; Type: EXPERIMENTAL; Interventions: Behavioral: Counselor-assisted problem solving (CAPS) | Arm Label: IRC; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Internet-resource comparison (IRC) | Intervention Type: BEHAVIORAL; Name: Counselor-assisted problem solving (CAPS); Assigned to Arm(s): CAPS | Intervention Type: BEHAVIORAL; Name: Internet-resource comparison (IRC); Assigned to Arm(s): IRC
C: Arm Label: Active Comparator: Internet Resources Comparison (IRC); Type: EXPERIMENTAL; Interventions: Behavioral: Internet Resources Comparison (IRC) | Arm Label: I-InTERACT; Type: EXPERIMENTAL; Interventions: Behavioral: Internet-based Interacting Together Everyday: Recovery After Childhood TBI (I-InTERACT) | Arm Label: I-InTERACT Express; Type: EXPERIMENTAL; Interventions: Behavioral: Internet-based-Interacting Together Everyday, Recovery after Childhood TBI Express (I-InTERACT Express) | Intervention Type: BEHAVIORAL; Name: Internet-based Interacting Together Everyday: Recovery After Childhood TBI (I-InTERACT); Assigned to Arm(s): I-InTERACT | Intervention Type: BEHAVIORAL; Name: Internet-based-Interacting Together Everyday, Recovery after Childhood TBI Express (I-InTERACT Express); Assigned to Arm(s): I-InTERACT Express | Intervention Type: BEHAVIORAL; Name: Internet Resources Comparison (IRC); Assigned to Arm(s): Active Comparator: Internet Resources Comparison (IRC)
D: Arm Label: CALMA; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CALMA plus, Behavioral: CALMA | Arm Label: Calma plus; Type: EXPERIMENTAL; Interventions: Behavioral: CALMA plus | Intervention Type: BEHAVIORAL; Name: CALMA plus; Assigned to Arm(s): CALMA, Calma plus | Intervention Type: BEHAVIORAL; Name: CALMA; Assigned to Arm(s): CALMA

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Mental Health Outcomes of Child Brain Injury
Brief Summary: This study will evaluate the effectiveness of an Internet-based psychosocial treatment in improving problem-solving, communication skills, stress management strategies, and coping among children who have had a traumatic brain injury and their families.


Options:
A: Arm Label: family diabetes management intervention; Type: EXPERIMENTAL; Interventions: Behavioral: family diabetes management intervention | Intervention Type: BEHAVIORAL; Name: family diabetes management intervention; Assigned to Arm(s): family diabetes management intervention
B: Arm Label: CAPS; Type: EXPERIMENTAL; Interventions: Behavioral: Counselor-assisted problem solving (CAPS) | Arm Label: IRC; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Internet-resource comparison (IRC) | Intervention Type: BEHAVIORAL; Name: Counselor-assisted problem solving (CAPS); Assigned to Arm(s): CAPS | Intervention Type: BEHAVIORAL; Name: Internet-resource comparison (IRC); Assigned to Arm(s): IRC
C: Intervention Type: BEHAVIORAL; Name: Problem-Solving Skills Training; Assigned to Arm(s): N/A
D: Arm Label: Multisystemic Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Multisystemic Therapy | Arm Label: Standard Medical Care (TAU); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Multisystemic Therapy; Assigned to Arm(s): Multisystemic Therapy

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Center, Double-Blind Study to Evaluate the Safety, Efficacy and Pharmacokinetics of the Human Anti-TNF Monoclonal Antibody Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease
Brief Summary: The purpose of this study is to determine Efficacy, Pharmacokinetics, and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: adalimumab | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: ciprofloxacin | Intervention Type: DRUG; Name: adalimumab; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: ciprofloxacin; Assigned to Arm(s): 2
B: Arm Label: Open-label adalimumab (Week 0 to Week 4); Type: ACTIVE_COMPARATOR; Interventions: Biological: Adalimumab | Arm Label: Low-Dose Adalimumab: 20 mg or 10 mg eow (Week 4 to Week 52); Type: ACTIVE_COMPARATOR; Interventions: Biological: Adalimumab | Arm Label: High-Dose Adalimumab: 40 mg or 20 mg eow (Week 4 to Week 52); Type: ACTIVE_COMPARATOR; Interventions: Biological: Adalimumab | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Open-label adalimumab (Week 0 to Week 4) | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Low-Dose Adalimumab: 20 mg or 10 mg eow (Week 4 to Week 52) | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): High-Dose Adalimumab: 40 mg or 20 mg eow (Week 4 to Week 52)
C: Arm Label: DB Adalimumab 40 mg eow; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Arm Label: Placebo eow; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: OL Adalimumab 40 mg eow; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): DB Adalimumab 40 mg eow, OL Adalimumab 40 mg eow | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo eow
D: Arm Label: Adalimumab 160 mg/80 mg; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Arm Label: Adalimumab 80 mg/40 mg; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: placebo | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Adalimumab 160 mg/80 mg | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Adalimumab 80 mg/40 mg | Intervention Type: BIOLOGICAL; Name: placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Study to Compare the Safety and Efficacy of RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed on VEGF Receptor Tyrosine Kinase Inhibitor
Brief Summary: To assess whether daily treatment with RAD001 could slow the growth and spread of metastatic carcinoma of the kidney. The safety of RAD001 was also to be studied in this trial.


Options:
A: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon-alfa | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: SU011248 | Intervention Type: DRUG; Name: Interferon-alfa; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: SU011248; Assigned to Arm(s): 1
B: Intervention Type: DRUG; Name: Sutent; Assigned to Arm(s): N/A
C: Arm Label: RAD001 +BSC; Type: EXPERIMENTAL; Interventions: Drug: RAD001 | Arm Label: Placebo (plus BSC); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: RAD001; Assigned to Arm(s): RAD001 +BSC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (plus BSC)
D: Arm Label: Sorafenib (Nexavar, BAY43-9006); Type: EXPERIMENTAL; Interventions: Drug: Sorafenib (Nexavar, BAY43-9006) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sorafenib (Nexavar, BAY43-9006); Assigned to Arm(s): Sorafenib (Nexavar, BAY43-9006) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-labeled, Randomized, Two-dose, Parallel Group Trial of Ofatumumab, a Fully Human Monoclonal Anti-CD20 Antibody, in Combination With Fludarabine and Cyclophosphamide, in Patients With Previously Untreated B-cell CLL
Brief Summary: To investigate the safety and efficacy of two dose regimes of ofatumumab in combination with chemotherapy in previously untreated patients with B-CLL


Options:
A: Arm Label: Fludarabine+Cyclophosphamide+Rituximab (FCR); Type: EXPERIMENTAL; Interventions: Drug: Rituximab, Drug: Cyclophosphamide, Drug: Fludarabine Phosphate | Arm Label: Fludarabine+Cyclophosphamide (FC); Type: ACTIVE_COMPARATOR; Interventions: Drug: Cyclophosphamide, Drug: Fludarabine Phosphate | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Fludarabine+Cyclophosphamide+Rituximab (FCR) | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Fludarabine+Cyclophosphamide (FC), Fludarabine+Cyclophosphamide+Rituximab (FCR) | Intervention Type: DRUG; Name: Fludarabine Phosphate; Assigned to Arm(s): Fludarabine+Cyclophosphamide (FC), Fludarabine+Cyclophosphamide+Rituximab (FCR)
B: Arm Label: Active Comparator 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ofatumumab 500mg, Drug: Fludarabine, Drug: Cyclophosphamide | Arm Label: Active Comparator 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ofatumumab 1000mg, Drug: Fludarabine, Drug: Cyclophosphamide | Intervention Type: DRUG; Name: Ofatumumab 500mg; Assigned to Arm(s): Active Comparator 1 | Intervention Type: DRUG; Name: Ofatumumab 1000mg; Assigned to Arm(s): Active Comparator 2 | Intervention Type: DRUG; Name: Fludarabine; Assigned to Arm(s): Active Comparator 1, Active Comparator 2 | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Active Comparator 1, Active Comparator 2
C: Arm Label: ofatumumab + chlorambucil; Type: EXPERIMENTAL; Interventions: Drug: chlorambucil, tablets, Drug: ofatumumab (GSK1841157) infusion | Arm Label: chlorambucil; Type: ACTIVE_COMPARATOR; Interventions: Drug: chlorambucil, tablets | Intervention Type: DRUG; Name: chlorambucil, tablets; Assigned to Arm(s): chlorambucil, ofatumumab + chlorambucil | Intervention Type: DRUG; Name: ofatumumab (GSK1841157) infusion; Assigned to Arm(s): ofatumumab + chlorambucil
D: Arm Label: ofatumumab; Type: EXPERIMENTAL; Interventions: Drug: ofatumumab | Intervention Type: DRUG; Name: ofatumumab; Assigned to Arm(s): ofatumumab

Answer: B